Alex Ridgway

North Bristol NHS Trust

Papers

1

Total Citations

3

H-Index

1

About

Alex Ridgway is a urological surgeon and researcher whose work centers on optimizing perioperative care for patients undergoing major oncologic surgery, with a particular focus on robot-assisted radical cystectomy (RARC). His key research areas include preoperative risk stratification, the role of cardiopulmonary exercise testing (CPET), and the utility of comorbidity indices in predicting surgical outcomes. Ridgway’s major contribution lies in systematically evaluating how objective physiological measures, such as CPET-derived data, compare to traditional comorbidity scores like the Charlson Comorbidity Index (CCI) in forecasting postoperative complications and length of stay. His landmark 2022 study, which has garnered 3 citations, provides critical evidence that CPET may offer superior predictive value for adverse outcomes in patients undergoing RARC with intracorporeal urinary diversion—a technically demanding procedure. This work has direct implications for clinical decision-making, helping surgeons identify high-risk patients and tailor perioperative management. Ridgway’s research bridges the gap between exercise physiology and surgical oncology, offering a more nuanced approach to preoperative assessment. His contributions are particularly notable for advancing patient safety and personalized care in complex urological cancer surgery.

Research Focus

Key Achievements

1
H-Index
1
Papers
3
Total Citations
3
Avg Citations/Paper
🏆 Most Cited Paper
The impact of cardiopulmonary exercise testing (CPET) and Charlson comorbidity index (CCI) in a large contemporary cohort of patients undergoing robot‐assisted radical cystectomy and intracorporeal urinary diversion (RARC‐ICUD)
3 citations · 2022
📈 Most Prolific Year: 2022 (1 Papers)
🤝 Key Collaborators: 6
🏛 Institutions: North Bristol NHS Trust

Top Papers

  1. 1

Key Collaborators

Contact & Links

Available for collaboration
Content generated · 11 days ago